Editas Medicine to Participate in Upcoming Investor Conferences
Editas Medicine (Nasdaq: EDIT), a clinical-stage gene editing company, has announced its participation in three major healthcare investor conferences. The company will be featured in fireside chat sessions at Guggenheim's Inaugural Healthcare Innovation Conference on November 12 at 4:00 p.m. ET in Boston, the Stifel 2024 Healthcare Conference on November 19 at 1:50 p.m. ET in New York, and the 7th Annual Evercore ISI HealthCONx Conference on December 3 at 1:20 p.m. ET in Coral Gables. Live webcasts will be available on the company's website, with replays accessible for approximately 30 days after each event.
Editas Medicine (Nasdaq: EDIT), un'azienda di editing genetico in fase clinica, ha annunciato la sua partecipazione a tre importanti conferenze per investitori nel settore sanitario. L'azienda sarà presentata in sessioni di chiacchierata informale durante la Conferenza Inaugurale sull'Innovazione Sanitaria di Guggenheim il 12 novembre alle 16:00 ET a Boston, la Conferenza Sanitaria Stifel 2024 il 19 novembre alle 13:50 ET a New York, e la 7a Conferenza Annuale Evercore ISI HealthCONx il 3 dicembre alle 13:20 ET a Coral Gables. I webcast dal vivo saranno disponibili sul sito web dell'azienda, con repliche accessibili per circa 30 giorni dopo ciascun evento.
Editas Medicine (Nasdaq: EDIT), una empresa de edición genética en etapa clínica, ha anunciado su participación en tres conferencias importantes de inversionistas en el sector salud. La empresa será destacada en sesiones de charla informal en la Conferencia Inaugural de Innovación en Salud de Guggenheim el 12 de noviembre a las 4:00 p.m. ET en Boston, la Conferencia de Salud Stifel 2024 el 19 de noviembre a la 1:50 p.m. ET en Nueva York, y la 7ª Conferencia Anual Evercore ISI HealthCONx el 3 de diciembre a la 1:20 p.m. ET en Coral Gables. Las transmisiones en vivo estarán disponibles en el sitio web de la empresa, con repeticiones accesibles durante aproximadamente 30 días después de cada evento.
Editas Medicine (Nasdaq: EDIT), 임상 단계의 유전자 편집 회사가 주요 의료 투자자 회의 3곳에 참가한다고 발표했습니다. 이 회사는 11월 12일 오후 4:00 ET에 보스턴에서 열리는 구겐하임 최초의 의료 혁신 회의, 11월 19일 오후 1:50 ET에 뉴욕에서 개최되는 스티펠 2024 의료 회의, 그리고 12월 3일 오후 1:20 ET에 코랄 게이bles에서 열리는 제7회 연례 에버코어 ISI 헬스콘x 회의에서 장외 대화 세션에 등장합니다. 실시간 웹캐스트는 회사 웹사이트에서 제공되며, 각 이벤트 후 약 30일 동안 다시 볼 수 있습니다.
Editas Medicine (Nasdaq: EDIT), une entreprise de modification génétique en phase clinique, a annoncé sa participation à trois grandes conférences pour investisseurs dans le secteur de la santé. L'entreprise sera présentée lors de discussions informelles à la Conférence Inaugurale sur l'Innovation Santé de Guggenheim le 12 novembre à 16h00 ET à Boston, à la Conférence Santé Stifel 2024 le 19 novembre à 13h50 ET à New York, et à la 7ème Conférence Annuelle Evercore ISI HealthCONx le 3 décembre à 13h20 ET à Coral Gables. Des webcasts en direct seront disponibles sur le site Web de l'entreprise, avec des rediffusions accessibles pendant environ 30 jours après chaque événement.
Editas Medicine (Nasdaq: EDIT), ein Unternehmen für die genetische Bearbeitung in der klinischen Phase, hat seine Teilnahme an drei wichtigen Investorenkonferenzen im Gesundheitswesen bekannt gegeben. Das Unternehmen wird in informellen Gesprächsrunden auf der Ersten Gesundheitsinnovationskonferenz von Guggenheim am 12. November um 16:00 Uhr ET in Boston, der Stifel Gesundheitskonferenz 2024 am 19. November um 13:50 Uhr ET in New York und der 7. jährlichen Evercore ISI HealthCONx Konferenz am 3. Dezember um 13:20 Uhr ET in Coral Gables vorgestellt. Live-Webcasts werden auf der Website des Unternehmens verfügbar sein, mit Aufzeichnungen, die etwa 30 Tage nach jeder Veranstaltung zugänglich sind.
- None.
- None.
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that management will participate in the following upcoming investor conferences in November and December:
- Guggenheim’s Inaugural Healthcare Innovation Conference
Format: Fireside Chat
Date: Tuesday, November 12
Time: 4:00 p.m. ET
Location: Boston, MA
- Stifel 2024 Healthcare Conference
Format: Fireside Chat
Date: Tuesday, November 19
Time: 1:50 p.m. ET
Location: New York, NY
- 7th Annual Evercore ISI HealthCONx Conference
Format: Fireside Chat
Date: Tuesday, December 3
Time: 1:20 p.m. ET
Location: Coral Gables, FL
To access the live webcasts of Editas Medicine’s presentations, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following each event.
About Editas Medicine
As a clinical-stage gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
FAQ
What investor conferences is Editas Medicine (EDIT) attending in November and December 2024?
How can investors watch Editas Medicine's (EDIT) conference presentations?
What is the format of Editas Medicine's (EDIT) presentations at the upcoming conferences?
